Our work
It is very common to find gaps in physico-chemical and (eco)toxicological data sets, which preclude confident hazard and risk assessment. Testing on vertebrate animals has ethical concerns across all sectors, and is banned for cosmetics marketed in Europe. Laboratory animal studies are in any case often undesirable for more mundane reasons such as time and costs. Where possible, we strive to help clients fill data gaps without a potentially costly and animal-intensive trip to the testing laboratory.
Computer models have been developed to predict the toxicological characteristics of an untested compound based on knowledge of the activity of others. (Q)SAR modelling is gaining regulatory acceptance. Indeed, in some sectors (Q)SAR analysis is a requirement. It can also be used as a screening exercise to inform a company on whether laboratory testing is scientifically justified.
Interpretation
Our vast experience in applying these toxicity models is matched by our expertise in interpreting the results. The limitations of (Q)SAR models must be understood and described, and the results should be applied appropriately. (Q)SAR results should always be interpreted in the context of any literature identified in searches of databases such as bibra’s own TRACE. Our toxicologists perform robust sanity checks on all of the outputs to ensure that predictions are sensible and consistent with our on-the-job knowledge and expectations.
Expertise/Leadscope
Bibra is an expert consulting partner of Leadscope, which we use frequently in-house, including for the evaluation of DNA-reactive compounds (particularly pharmaceutical impurities), in accordance with ICH guidance M7. Toxicology Director, Pete Watts and Senior Toxicologist, Chris Waine, are regular contributors to Leadscope’s continuing development through participation in working groups, and have been involved in several publications in the peer-reviewed literature.
Models
Our in-house team and expert partners can generate (Q)SAR predictions using a range of in silico models, including:
Helpful links
In silico toxicology protocols
Myatt et al. 2018: Regulatory Toxicology and Pharmacology (volume 96)
Genetic toxicology in silico protocol
Hasselgren et al. 2019: Regulatory Toxicology and Pharmacology (volume 107)
Some of our case studies in this area
A human health risk assessment of API-related impurities
Case study
Whilst developing an inhalation spray drug product, the client identified two impurities with chemical structures related to the Active Pharmaceutical Ingredient (API). Click through to read more about how we dealt with this interesting project.
Human health risk assessment of unknown contamination
Case study
The client reported that small “brown spots” had been observed on the inside surface of a batch of aluminium tubes that contain a topical drug product. The source and chemical composition of the brown spots was unknown. Click through to read more about how we dealt with this interesting project.
EU Potential Changes to TPD
Blog articles
In April 2026, the European Commission published its evaluation of the Tobacco Products Directive and Tobacco Advertising Directive (TPD) and Tobacco Advertising Directive (TAD). The evaluation concluded that, while the existing framework has made a positive contribution to the protection of public health, it is increasingly challenged by the emergence and growing use of novel tobacco and nicotine products.
